Trial Profile
BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis - PK Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Apr 2022
Price :
$35
*
At a glance
- Drugs Ridaforolimus (Primary) ; Zotarolimus
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Pharmacokinetics
- Acronyms BIONICS
- Sponsors Medinol
- 05 Apr 2022 Status changed from active, no longer recruiting to completed.
- 14 Jun 2020 Status changed from recruiting to active, no longer recruiting.
- 03 Jul 2016 Status changed from not yet recruiting to recruiting.